Arcturus Therapeutics Holdings Inc. ARCT
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a rare genetic drug developer. Its lead program, ARCT-032 (LUNAR-CF), is in Phase 2 for Cystic fibrosis (CFTR mRNA, inhaled).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ARCT-032 (LUNAR-CF) | Cystic fibrosis | RNA (siRNA/ASO/mRNA) | Phase 2 |
| ARCT-810 (LUNAR-OTC) | Ornithine transcarbamylase deficiency | RNA (siRNA/ASO/mRNA) | Phase 2 |
| H5N1 pandemic influenza sa-mRNA (BARDA) | Pandemic influenza | vaccine | Phase 1 |
| LUNAR-FLU | Seasonal influenza (formerly partnered with CSL Seqirus) | vaccine | Phase 1 |
Recent results and decisions
- Aug 6, 2026completed enrollment ARCT-810 Phase 2 OTC deficiency study completed enrollment and all subjects completed study drug dosing.
ARCT-810, an mRNA therapeutic candidate for OTC deficiency, has completed enrollment of the ongoing Phase 2 study, and all enrolled subjects have completed study drug dosing.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 rare genetic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.